GH Research is a pre-revenue, cash-burning biotech with very weak quality (1.6/10) and a stock down 42% from its high, but with a consistent record of narrowing losses versus estimates and an analyst target 106.5% above the price.
Thesis pillars
- Large Analyst Upside Gap→Stable
- Pre Revenue Cash Burn→Stable
- Losses Near Estimates→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026
GH Research PLC (GHRS) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $20.71: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 5.3:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 5.00; Below-average business quality; Below long-term trend.
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical... Read more
Sell if holding. Engine safety override at $20.71: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 5.3:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 5.00; Below-average business quality; Below long-term trend. Chart setup: RSI 51 mid-range, Bollinger mid-band. Score 5.7/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — GH Research PLC
Latest news
- NEWS Guggenheim Maintains Buy on GH Research, Raises Price Target to $40 — benzinga Aug 7, 2026 positive
- NEWS Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $40 — benzinga Aug 7, 2026 positive
- NEWS Needham Maintains Buy on GH Research, Raises Price Target to $39 — benzinga Aug 6, 2026 positive
- NEWS GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate — benzinga Aug 6, 2026 positive
- NEWS Wells Fargo Initiates Coverage On GH Research with Overweight Rating, Announces Price Target of $44 — benzinga Jul 27, 2026 positive
Generated 2026-10-29T12:43:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $20.71: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 5.3:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 5.00; Below-average business quality; Below long-term trend. Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $19.26. Score 5.7/10, moderate confidence.
Analyst target: $37.31 (+80.2% upside). Prior stop was $19.26. Stop-loss: $19.26.
Quality below floor (1.6 < 4.0); Value-trap signals (2/5): High leverage (D/E 6.0), Material insider selling (6 sells, 4.87% of cap).
GH Research PLC trades at a P/E of N/A (forward -11.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover GHRS with a consensus score of 4.2/5. Average price target: $43.
What does GH Research PLC do?GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops...
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.